PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Researchers use biophysics to design new vaccines against RSV and related respiratory viruses

Scripps Research scientists improved existing vaccines by analyzing the molecular structure and stability of viral proteins.

2024-11-19
(Press-News.org)  

LA JOLLA, CA—In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can cause severe pneumonia and even death.

Vaccines against both viruses, however, have been difficult to design. Now, Scripps Research scientists have analyzed the structure and stability of a critical RSV and hMPV protein to better design vaccines that target it. Their research, published in Nature Communications on November 16, 2024, points toward RSV vaccines that may be more effective than existing ones, as well as a vaccine against hMPV, for which there are no commercially available options.  

“Creating a combination vaccine for these viruses could significantly reduce viral hospitalizations for both babies and the elderly,” says study senior author Jiang Zhu, PhD, an associate professor in the Department of Integrative Structural and Computational Biology at Scripps Research. “This could alleviate the overall health burden during flu season, which is also when most RSV and hMPV cases occur.”

Scientists have long attempted to create vaccines that coax the immune system into recognizing the fusion (F) proteins present on the surfaces of RSV, hMPV and related viruses. These proteins play a key role in letting the viruses infect human cells. However, the F protein has a delicate structure that changes rapidly from a “pre-fusion” form to a “post-fusion” form when the viruses fuse with cells. Ideally, a vaccine would teach the immune system to recognize the closed pre-fusion F protein so it could stop infection.

“The problem is that this pre-fusion structure is so fragile and volatile,” says Zhu. “If you change the environment even a tiny bit, the protein is like a transformer that suddenly flips from a car into a robot.”

This means that scientists cannot simply use an isolated pre-fusion F protein as a vaccine—its structure would change too quickly for the immune system to react. And a vaccine targeting the post-fusion version of the protein wouldn’t teach the immune system to attack the virus before it has a chance to infect the body.

Zhu, who has a background in biophysics and has recently designed new vaccines for viruses including HIV, SARS-CoV-2 and hepatitis C, thought that if he could understand the precise mechanism of why the pre-fusion F protein was so unstable, especially why it is so easy to open, he could make a more stable form—and, in turn, a better vaccine.

Zhu and his research team first analyzed the F proteins used in development of four existing RSV vaccines—the commercially available Arexvy, mResvia and Abrysvo, and an experimental vaccine that has reached phase 3 trials. They discovered that some of the pre-fusion F proteins appeared to be unstable and sometimes converted to an open form, or even less desirable, a post-fusion form. A detailed structural analysis revealed an “acidic patch” sitting at the center of the pre-fusion structure with three positively charged molecules repelling each other, ready to push open the RSV F protein at the slightest perturbation, like a spring-loaded transformer.

“This is an incredible trait for a virus to acquire during evolution to control the movement of its key protein,” says Zhu. “Luckily, it’s also something we can overcome, either with brute force or, better, with a smart mutation directly tackling the source of the problem, the acidic patch.”

Zhu reengineered the RSV F protein by changing a pair of molecules at its center, turning the outward repelling force into an attracting one. Then, his team showed that this new F protein was both more stable in the lab and successfully worked to vaccinate mice against RSV.

“This suggests that we might be able to take a similar approach for other viral F proteins,” says Zhu. “At the very least, we can look for similar repulsive patches in their structure as we design vaccines.”

In the hMPV F protein, Zhu didn’t find the same patch of repellant molecules—instead, he used a strong chemical bond as a “brute force” solution to hold the protein together. Once again, the modified protein was stable enough to remain intact as a vaccine.

In future studies, Zhu plans to develop an experimental vaccine using a self-assembling protein nanoparticle (SApNP) platform reported in his recent work to deliver the RSV and hMPV F proteins to the human body. “That would be our next-generation RSV/hMPV combo vaccine,” says Zhu.

In addition to Zhu, authors of the study, “Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus,” include Yi-Zong Lee, Jerome Han, Yi-Nan Zhang, Garrett Ward, Keegan Braz Gomes, Sarah Auclair, Robyn L. Stanfield, Linling He, and Ian A. Wilson of Scripps.

This work was supported by funding from Uvax Bio. Uvax Bio, a spin-off vaccine company from Scripps Research, employs proprietary platform technology invented in Zhu’s lab to develop and commercialize prophylactic vaccines for various infectious diseases.

About Scripps Research

Scripps Research is an independent, nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at www.scripps.edu.

END


ELSE PRESS RELEASES FROM THIS DATE:

New study highlights physician perspectives on emerging anti-amyloid treatments for Alzheimer’s disease in Israel

New study highlights physician perspectives on emerging anti-amyloid treatments for Alzheimer’s disease in Israel
2024-11-19
November 19, 2024 - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel – In a recent study, Tel Aviv Sourasky Medical Center has shed light on physician attitudes toward novel anti-amyloid treatments (ATT) for Alzheimer’s disease (AD), revealing a spectrum of opinions across key specialties. With Israel’s health system structured to provide universal healthcare, the high out-of-pocket costs for new AD therapies have raised questions among medical professionals about the feasibility and practicality of implementing these treatments. The study, conducted ...

U of M research finds creativity camp improves adolescent mental health, well-being

2024-11-19
MINNEAPOLIS/ST. PAUL (11/19/2024) — Published in Child Psychiatry and Human Development, a research team led by the University of Minnesota Medical School found that Creativity Camp, a two-week arts intervention delivered as a day camp, had a positive impact on mental health and well-being in adolescents with depression.  The idea behind the study is that engaging in the arts offers a pathway for exploring and expanding new ways of thinking, developing insights and sparking self-discovery. “As a clinician, I am deeply aware of the urgent need for new treatment options for teens with depression. The findings in this report are promising, and I hope they ...

How human brain functional networks emerge and develop during the birth transition

How human brain functional networks emerge and develop during the birth transition
2024-11-19
Brain-imaging data collected from fetuses and infants has revealed a rapid surge in functional connectivity between brain regions on a global scale at birth, possibly reflecting neural processes that support the brain’s ability to adapt to the external world, according to a study published November 19th, in the open-access journal PLOS Biology led by Lanxin Ji and Moriah Thomason from the New York University School of Medicine, USA. Understanding the sequence and timing of brain functional network ...

Low-dose ketamine shows promise for pain relief in emergency department patients

2024-11-19
Des Plaines, IL — A new study that investigates low-dose ketamine (LDK) as an adjunct to morphine for treating acute pain has been published in the October issue of Academic Emergency Medicine (AEM), the peer-reviewed journal of the Society for Academic Emergency Medicine (SAEM). The study, titled Low-dose ketamine as an adjunct to morphine: A randomized controlled trial among patients with and without current opioid use highlights the potential of low-dose ketamine as a valuable tool in pain management, providing a safe and effective option for emergency medicine physicians managing acute pain.  Pain remains one of the most common and challenging complaints ...

Lifestyle & risk factor changes improved AFib symptoms, not burden, over standard care

2024-11-19
Research Highlights: A clinical trial with adults who have atrial fibrillation (AFib) and an implanted heart device found similar improvements to the amount of time they experienced arrhythmia regardless of whether they received standard care (education pamphlets about healthy diet and exercise), followed a lifestyle/risk factor modification program, or took metformin and followed a lifestyle/risk factor modification program. AFib burden, a measure of how much time a patient experiences atrial arrhythmia, improved during the treatment period — particularly in the standard of care and lifestyle risk factor modification groups. Lifestyle and risk factor modification was associated ...

Researchers discover new cognitive blueprint for making and breaking habits

2024-11-19
Cognitive neuroscientists in Trinity College Dublin have published new research describing a brand new approach to making habit change achievable and lasting.  This innovative framework has the potential to significantly improve approaches to personal development, as well as the clinical treatment of compulsive disorders (for example obsessive compulsive disorder, addiction, and eating disorders). The research was led by Dr Eike Buabang, Postdoctoral Research Fellow in the lab of Professor Claire Gillan in the School of Psychology and has been published as a paper, Leveraging ...

In a small international trial, novel oral medication muvalaplin lowered Lp(a)

2024-11-19
Research Highlights: The oral medication muvalaplin may safely lower high levels of lipoprotein(a), also known as Lp(a), an independent, inherited risk factor for cardiovascular disease. Muvalaplin is a small molecule inhibitor that prevents the bonding of the two protein components that combine to make Lp(a). There are no currently FDA-approved medications to lower Lp(a) levels, though other medications are currently being evaluated in clinical trials. Muvalaplin is the first oral medication developed to lower Lp(a) levels. Results ...

Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies

Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies
2024-11-19
WEST LAFAYETTE, Ind. — Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies. A single intranasal dose of EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating the detectable virus within 24 hours. EV25 also has a window of efficacy of 96 hours postinfection, which is broader than the current standard of care. A ...

Most Medicare beneficiaries do not compare prescription drug plans – and may be sticking with bad plans

2024-11-19
Every fall, millions of Medicare beneficiaries have the chance to pick a new stand-alone prescription drug plan that may be better suited for them, but most stick with the same plan. A new study published today in Health Affairs Scholar suggests that 52% of Medicare beneficiaries with stand-alone Part D plans did not switch because they made no plan comparisons at all for 2024. Many of these beneficiaries (41%) also reported not knowing how to switch plans.   “Comparing these Medicare Part D plans is hard, so many beneficiaries just don’t do it. But beneficiaries who don’t compare plans may not notice if they are sticking with more expensive plans or ...

“What Would They Say?” video wins second place in international award for tobacco control advocacy

2024-11-19
DALLAS, Nov. 19, 2024 —“What Would They Say?” – the powerful spoken word poem produced on video by the American Heart Association, which is celebrating 100 years of lifesaving service as the world’s leading voluntary organization focused on heart and brain health, has taken second place in the 4th Annual Anthem Awards winning the Silver Award in the Education, Art & Culture Campaign - Non-Profit Community Engagement category. This international recognition celebrates the Association’s impactful work and historic commitment ...

LAST 30 PRESS RELEASES:

Scientists unlock secrets behind flowering of the king of fruits

Texas A&M researchers illuminate the mysteries of icy ocean worlds

Prosthetic material could help reduce infections from intravenous catheters

Can the heart heal itself? New study says it can

Microscopic discovery in cancer cells could have a big impact

Rice researchers take ‘significant leap forward’ with quantum simulation of molecular electron transfer

Breakthrough new material brings affordable, sustainable future within grasp

How everyday activities inside your home can generate energy

Inequality weakens local governance and public satisfaction, study finds

Uncovering key molecular factors behind malaria’s deadliest strain

UC Davis researchers help decode the cause of aggressive breast cancer in women of color

Researchers discovered replication hubs for human norovirus

SNU researchers develop the world’s most sensitive flexible strain sensor

Tiny, wireless antennas use light to monitor cellular communication

Neutrality has played a pivotal, but under-examined, role in international relations, new research shows

Study reveals right whales live 130 years — or more

Researchers reveal how human eyelashes promote water drainage

Pollinators most vulnerable to rising global temperatures are flies, study shows

DFG to fund eight new research units

Modern AI systems have achieved Turing's vision, but not exactly how he hoped

Quantum walk computing unlocks new potential in quantum science and technology

Construction materials and household items are a part of a long-term carbon sink called the “technosphere”

First demonstration of quantum teleportation over busy Internet cables

Disparities and gaps in breast cancer screening for women ages 40 to 49

US tobacco 21 policies and potential mortality reductions by state

AI-driven approach reveals hidden hazards of chemical mixtures in rivers

Older age linked to increased complications after breast reconstruction

ESA and NASA satellites deliver first joint picture of Greenland Ice Sheet melting

Early detection model for pancreatic necrosis improves patient outcomes

Poor vascular health accelerates brain ageing

[Press-News.org] Researchers use biophysics to design new vaccines against RSV and related respiratory viruses
Scripps Research scientists improved existing vaccines by analyzing the molecular structure and stability of viral proteins.